The Melbourne Diabetes Prevention Study (MDPS): study protocol for a randomized controlled trial

Trials

James A Dunbar¹  Erkki Vartiainen⁴  Benjamin Philpot¹  Sharleen O’Reilly²  Catherine M Bennett²  Rob Carter⁵  Elizabeth Stewart²  Edward D Janus³  Andrea Hernan¹  Nathalie Davis-Lameloise¹ 

[1] Greater Green Triangle University Department of Rural Health, Flinders University and Deakin University, PO Box 423, 3280, Warrnambool, VIC, Australia;Faculty of Health, Deakin University, 221 Burwood Highway, 3125, Burwood, VIC, Australia;Department of Medicine, North West Academic Centre, The University of Melbourne, Western Hospital, Melbourne, Corner Eleanor & Marion Sts, 3011, Footscray, VIC, Australia;National Institute for Health and Welfare, Mannerheimintie 166, 00300, Helsinki, Finland;Deakin Health Economics, Deakin Strategic Research Centre - Population Health, Faculty of Health, Deakin University, 221 Burwood Highway, 3125, Burwood, VIC, Australia

关键词: Intervention;    Lifestyle;    Prevention;    Type 2 diabetes;    Randomized controlled trial;    Protocol;   

Others  :  1094862
DOI  :  10.1186/1745-6215-14-31

 received in 2012-06-14, accepted in 2013-01-16,  发布年份 2013

【 摘 要 】

Background

Worldwide, type 2 diabetes (T2DM) prevalence has more than doubled over two decades. In Australia, diabetes is the second highest contributor to the burden of disease. Lifestyle modification programs comprising diet changes, weight loss and moderate physical activity, have been proven to reduce the incidence of T2DM in high risk individuals.

As part of the Council of Australia Governments, the State of Victoria committed to develop and support the diabetes prevention program ‘Life! Taking action on diabetes’ (Life!) which has direct lineage from effective clinical and implementation trials from Finland and Australia. The Melbourne Diabetes Prevention Study (MDPS) has been set up to evaluate the effectiveness and cost-effectiveness of a specific version of the Life! program.

Methods/design

We intend to recruit 796 participants for this open randomized clinical trial; 398 will be allocated to the intervention arm and 398 to the usual care arm. Several methods of recruitment will be used in order to maximize the number of participants. Individuals aged 50 to 75 years will be screened with a risk tool (AUSDRISK) to detect those at high risk of developing T2DM. Those with existing diabetes will be excluded. Intervention participants will undergo anthropometric and laboratory tests, and comprehensive surveys at baseline, following the fourth group session (approximately three months after the commencement of the intervention) and 12 months after commencement of the intervention, while control participants will undergo testing at baseline and 12 months only.

The intervention consists of an initial individual session followed by a series of five structured-group sessions. The first four group sessions will be carried out at two week intervals and the fifth session will occur eight months after the first group session. The intervention is based on the Health Action Process Approach (HAPA) model and sessions will empower and enable the participants to follow the five goals of the Life! program.

Discussion

This study will determine whether the effect of this intervention is larger than the effect of usual care in reducing central obesity and cardiovascular risk factors and thus the risk of developing diabetes and cardiovascular disease. Also it will evaluate how these two options compare economically.

Trial registration

Australian New Zealand Clinical Trials Registry ACTRN12609000507280

【 授权许可】

   
2013 Davis-Lameloise et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes. Diabetes Care 2004, 27:1047-1053.
• [2]Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang Y-H, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose): National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011, 378:31-40.
• [3]Begg SJ, Vos T, Barker B, Stanley L, Lopez AD: Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust 2008, 188:36-40.
• [4]Vos T, Goss J, Begg S, Mann M: Projection of health care expenditure by disease: a case study from Australia. Background paper for United Nations 2007 World Economic and Social Survey publication. Brisbane: University of Queensland; 2007.
• [5]Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
• [6]Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
• [7]Li G, Hu Y, Yang W, Jiang Y, Wang J, Xiao J, Hu Z, Pan X, Howard BV, Bennett PH: Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and Diabetes Study. Diabetes Res Clin Pract 2002, 58:193-200.
• [8]Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, DREAM (Diabetes REducation Assessment with ramipril and roseglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
• [9]Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study Group: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679.
• [10]Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008, 371:1783-1789.
• [11]Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
• [12]Laatikainen T, Dunbar J, Chapman A, Kilkkinen A, Vartiainen E, Heistaro S, Philpot B, Absetz P, Bunker S, O'Neil A, Reddy P, Best JD, Janus ED: Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project. BMC Public Health 2007, 7:249. BioMed Central Full Text
• [13]Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljanen T, Uusitupa M, Tuomilehto J: Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999, 42:793-801.
• [14]Absetz P, Valve R, Oldenberg B, Heinonen H, Nissinen A, Fogelholm M, Ilvesmaki V, Talja M, Uutela A: Type 2 diabetes prevention in the “Real World” - one-year results of the GOAL implementation trial. Diabetes Care 2007, 30:2465-2470.
• [15]Baker IDI Heart and Diabetes Institute on behalf of the Australian State and Territory Governments: Australian Type 2 Diabetes Risk Assessment Tool, AUSDRISK. Canberra (ACT), Australia: Canberra (ACT), Australia; 2008. [Department of Health and Ageing]
• [16]Lindstrom J, Tuomilehto J: The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003, 26:725.
• [17]Chen L, Magliano DJ, Balkau B, Colagiuri S, Zimmet PZ, Tonkin AM, Mitchell P, Phillips PJ, Shaw JE: AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. Med J Aust 2010, 192:197-202.
• [18]Bandura A: Self-efficacy: The Exercise of Control. USA; Worth Publishers, New York, NY; 1997.
• [19]Schwarzer R: Self-efficacy in the adoption and maintenance of health behaviors: theoretical approaches and a new model. In Self-efficacy: Thought Control of Action. Washington, DC: Hemisphere; 1992:217-242.
• [20]Schwarzer R, Fuchs R: Self efficacy and health behaviors. In Predicting Health Behavior: Research and Practice with Social Cognition Models. Edited by Connor M, Norman P. Buckingham, UK: Open University Press; 1996:163-196.
• [21]Bandura A: Social Foundations of Thought and Action: A Social Cognitive Theory. Prentice Hall; Upper Saddle River, NJ, USA; 1986.
• [22]Prochaska JO, Velicer WF: Behavior change: the transtheoretical model of health behavior change. Am J Health Promot 1997, 12:38-48.
• [23]Feste C, Anderson R: Empowerment: from philosophy to practice. Patient Educ Couns 1995, 26:139.
• [24]Funnell M, Anderson R: Patient empowerment: a look back, a look ahead. Diabetes Educ 2003, 29:454-466.
• [25]Rappaport J: Terms of empowerment/exemplars of prevention: toward a theory for community psychology. Am J Community Psychol 1987, 15:121-148.
• [26]Oettingen G, Hönig G, Gollwitzer PM: Effective self-regulation of goal attainment. Int J Educ Res 2000, 33:705-732.
• [27]Oettingen G, Pak H, Schnetter K: Self-regulation of goal-setting: turning free fantasies about the future into binding goals. J Pers Soc Psychol 2001, 80:736-753.
• [28]Schwarzer R, Renner B: Social-cognitive predictors of health behavior: action self-efficacy and coping self-efficacy. Health Psychol 2000, 19:487-495.
• [29]Carter R, Vos T, Moodie M, Haby M, Magnus A, Mihalopoulos C: Priority setting in health: origins, description and application of the Australian Assessing Cost-Effectiveness initiative. Expert Rev Pharmacoecon Outcomes Res 2008, 8:593-617.
• [30]WHO: The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 1988, 41:105-114.
• [31]Tolonen H, Kuulasmaa K, Laatikainen T, Wolf H: European Health Risk Monitoring Project. Recommendation for indicators, international collaboration, protocol and manual of operations for chronic disease risk factor surveys. Helsinki, Finland: ; [National Public Health Institute (KTL)] http://www.ktl.fi/publications/ehrm/product2/product2.pdf webcite
• [32]Levesque CS, Williams GC, Elliot D, Pickering MA, Bodenhamer B, Finley PJ: Validating the theoretical structure of the Treatment Self-Regulation Questionnaire (TSRQ) across three different health behaviors. Health Educ Res 2007, 22:691-702.
• [33]Renner B, Schwarzer R: Risk and health behaviors: documentation of the Scales of the Research Project “Risk Appraisal Consequences in Korea” (RACK). In Risk and Health Behaviors: Documentation of the Scales of the Research Project “Risk Appraisal Consequences in Korea” (RACK). 2nd edition. International University Bremen & Freie Universität Berlin; 2005:1-55.
• [34]Schwarzer R, Renner B: Health-Specific Self-Efficacy Scales. 2008, 1-21. [Personal Communication]
• [35]Zimet GD, Dahlem NW, Zimet SG, Farley GK: The Multidimensional Scale of Perceived Social Support. J Pers Assess 1988, 52:30-41.
• [36]Quality of Life (AQoL). [ http://www.aqol.com.au/ webcite] URL accessed on 29.01.2013
• [37]Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
• [38]Webster C, Austin W: Health-related hardiness and the effect of a psycho-educational group on clients’ symptoms. J Psychiatr Ment Health Nurs 1999, 6:241-247.
• [39]Australian Institute of Health and Welfare: The Active Australia Survey: a guide and manual for implementation, analysis and reporting. Canberra (ACT), Australia; 2003. [AIHW]
• [40]Hodge A, Patterson AJ, Brown WJ, Ireland P, Giles G: The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle-aged women in a study of iron supplementation. Aust N Z J Public Health 2000, 24:576-583.
• [41]Lindstrom J, Neumann A, Sheppard KE, Gilis-Januszewska A, Greaves CJ, Handke U, Pajunen P, Puhl S, Polonen A, Rissanen A, Roden M, Stemper T, Telle-Hjellset V, Tuomilehto J, Velickiene D, Schwarz PE, Acosta T, Adler M, AlKerwi A, Barengo N, Barengo R, Boavida JM, Charlesworth K, Christov V, Claussen B, Cos X, Cosson E, Deceukelier S, Dimitrijevic-Sreckovic V, Djordjevic P: Take action to prevent diabetes–the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res 2010, 42(Suppl 1):S37-S55.
• [42]Paulweber B, Valensi P, Lindstrom J, Lalic NM, Greaves CJ, McKee M, Kissimova-Skarbek K, Liatis S, Cosson E, Szendroedi J, Sheppard KE, Charlesworth K, Felton AM, Hall M, Rissanen A, Tuomilehto J, Schwarz PE, Roden M, Paulweber M, Stadlmayr A, Kedenko L, Katsilambros N, Makrilakis K, Kamenov Z, Evans P, Gilis-Januszewska A, Lalic K, Jotic A, Djordevic P, Dimitrijevic-Sreckovic V: A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010, 42(Suppl 1):S3-S36.